Sai Life Sciences (SAILIFE) Stock Overview
Operates as a contract research, development, and manufacturing organization (CRDMO) in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for SAILIFE from our risk checks.
SAILIFE Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
100% Patient Improvement in trial puts this $16M Biotech on the radar
Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.
Sai Life Sciences Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹882.60 |
| 52 Week High | ₹943.00 |
| 52 Week Low | ₹636.10 |
| Beta | 0 |
| 1 Month Change | 4.02% |
| 3 Month Change | 11.33% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 15.43% |
Recent News & Updates
We Think Sai Life Sciences (NSE:SAILIFE) Can Stay On Top Of Its Debt
Sep 08
Sai Life Sciences Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Aug 12Shareholder Returns
| SAILIFE | IN Life Sciences | IN Market | |
|---|---|---|---|
| 7D | 2.8% | 1.8% | 1.5% |
| 1Y | n/a | -0.4% | -4.7% |
Return vs Industry: Insufficient data to determine how SAILIFE performed against the Indian Life Sciences industry.
Return vs Market: Insufficient data to determine how SAILIFE performed against the Indian Market.
Price Volatility
| SAILIFE volatility | |
|---|---|
| SAILIFE Average Weekly Movement | 5.2% |
| Life Sciences Industry Average Movement | 5.2% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in IN Market | 8.3% |
| 10% least volatile stocks in IN Market | 3.2% |
Stable Share Price: SAILIFE has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: SAILIFE's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 3,401 | Krishnam Kanumuri | www.sailife.com |
Sai Life Sciences Limited operates as a contract research, development, and manufacturing organization (CRDMO) in India and internationally. It provides medicinal chemistry, pharmacokinetics, manufacturing, and contract development services. The company was formerly known as SAI Advantium Pharma Limited and changed its name to Sai Life Sciences Limited in July 2006.
Sai Life Sciences Limited Fundamentals Summary
| SAILIFE fundamental statistics | |
|---|---|
| Market cap | ₹184.87b |
| Earnings (TTM) | ₹2.44b |
| Revenue (TTM) | ₹19.11b |
Is SAILIFE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SAILIFE income statement (TTM) | |
|---|---|
| Revenue | ₹19.11b |
| Cost of Revenue | ₹5.34b |
| Gross Profit | ₹13.78b |
| Other Expenses | ₹11.33b |
| Earnings | ₹2.44b |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 11.65 |
| Gross Margin | 72.07% |
| Net Profit Margin | 12.77% |
| Debt/Equity Ratio | 16.6% |
How did SAILIFE perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/04 18:40 |
| End of Day Share Price | 2025/10/03 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sai Life Sciences Limited is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Rahul Jeewani | IIFL Research |
| Alok Dalal | Jefferies LLC |
| Nischint Chawathe | Kotak Securities (Institutional Equities) |